Now published - link here Preprint Prevalent and persistent new-onset autoantibodies in mild to severe COVID-19 Abstract Autoantibodies have been shown to be implied in COVID-19 but the emerging autoantibody repertoire remains largely unexplored. We investigated the new-onset autoantibody repertoire in 525 healthcare workers and hospitalized COVID-19 patients in five time points over 16 months using proteome-wide and targeted protein and peptide arrays. Our results show that prevalent new-onset autoantibodies against a wide range of antigens emerged following SARS-CoV-2 infection in relation to pre-infectious baseline samples and remained elevated for at least 12 months. We demonstrated associations between distinct new-onset autoantibodies and neuropsychiatric symptoms post-COVID-19. Using epitope mapping, we determined the main epitopes of selected new-onset autoantibodies, validated them in independent cohorts of neuro-COVID and pre-pandemic healthy controls, and identified molecular mimicry between main epitopes and the conserved fusion peptide of the SARS-CoV-2 Spike glycoprotein. Our work describes the complexity and dynamics of the autoantibody repertoire emerging with COVID-19 and supports the need for continued analysis of the new-onset autoantibody repertoire to elucidate the mechanisms of the post-COVID-19 condition. https://www.medrxiv.org/content/10.1101/2024.02.15.24302857v1
I suspect that they have simply demonstrated that people with covid develop antibodies to Covid. Peptides are not a good way to look for autoantibodies of clinical relevance.
Now published as Prevalent and persistent new-onset autoantibodies in mild to severe COVID-19 Jernbom, August F.; Skoglund, Lovisa; Pin, Elisa; Sjöberg, Ronald; Tegel, Hanna; Hober, Sophia; Rostami, Elham; Rasmusson, Annica; Cunningham, Janet L.; Havervall, Sebastian; Thålin, Charlotte; Månberg, Anna; Nilsson, Peter Autoantibodies have been shown to be implied in COVID-19 but the emerging autoantibody repertoire remains largely unexplored. We investigated the newonset autoantibody repertoire in 525 healthcare workers and hospitalized COVID-19 patients at five time points over a 16-month period in 2020 and 2021 using proteome-wide and targeted protein and peptide arrays. Our results show that prevalent new-onset autoantibodies against a wide range of antigens emerged following SARS-CoV-2 infection in relation to pre-infectious baseline samples and remained elevated for at least 12 months. We found an increased prevalence of new-onset autoantibodies after severe COVID-19 and demonstrated associations between distinct new-onset autoantibodies and neuropsychiatric symptoms post-COVID-19. Using epitope mapping, we determined the main epitopes of selected new-onset autoantibodies, validated them in independent cohorts of neuro-COVID and pre-pandemic healthy controls, and identified sequence similarities suggestive of molecular mimicry between main epitopes and the conserved fusion peptide of the SARS-CoV-2 Spike glycoprotein. Our work describes the complexity and dynamics of the autoantibody repertoire emerging with COVID-19 and supports the need for continued analysis of the new-onset autoantibody repertoire to elucidate the mechanisms of the post-COVID-19 condition. Link | PDF (Nature Communications) [Open Access]
As anti-IFN IgG is implied in severe COVID-19, we specifically characterized the new-onset anti-IFN IgG response in our study. Considering all IFN subtypes, we found new-onset anti-IFN IgG in 3% of the baseline seronegative cohort, mainly consisting of anti-type I IFN IgG. Spoiler: GeneCards CALU MYO16 SNURF
I wouldn't worry too much. I doubt there are any of importance. The things you are li'ble to read in the bible, they ain't necessarily so.
Thanks for reassuring me. Genetics isn't my thing, that's obvious. Took me a while to figure out the second sentence. Before the crack of dawn, it dawned on me you were singing a George Gershwin song to me: how nice of you.
An author did a thread but blocked responses so it doesn’t look like the Thread unroll tool works on it.